|
2024 Conference Publication Real-world experience with Cladribine (Mavenclad) in the MSBase registryButzkueven, Helmut, Spelman, Tim, Van der Walt, Anneke, Hodgkinson, Suzanne, Ozakbas, Serkan, Alroughani, Raed, Kalincik, Tomas, Eichau, Sara, Boz, Cavit, Buzzard, Katherine, Habek, Mario, John, Nevin, Kermode, Allan G., Foschi, Matteo, McCombe, Pamela, Gerlach, Oliver, Prevost, Julie, Meca-Lallana, Jose E., Lapointe, Emmanuelle and Jarvinen, Elina (2024). Real-world experience with Cladribine (Mavenclad) in the MSBase registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
|
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase RegistryBarnett, Michael, van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Hodgkinson, Suzanne, McCombe, Pamela, Macdonell, Richard, Slee, Mark, Migocki, Margaret, Martel, Kate and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase Registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
|
2024 Conference Publication Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple SclerosisNelson, Morag, Butzkueven, Helmut, Van der Walt, Anneke, Broadley, Simon, Riley, Nicholas, Adlard, Nicholas, Merschhemke, Martin, Stoneman, Dee, McCombe, Pamela, Barnett, Michael, Walker, Rob, Samjoo, Imtiaz, Haltner, Anja and Drudge, Chris (2024). Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis. 16th Congress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis, Bangkok, Thailand, 30 October - 2 November 2024. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisRoos, Izanne, Sharmin, Sifat, Malpas, Charles, Ozakbas, Serkan, Lechner-Scott, Jeannette, Hodgkinson, Suzanne, Alroughani, Raed, Eichau Madueño, Sara, Boz, Cavit, van der Walt, Anneke, Butzkueven, Helmut, Buzzard, Katherine, Skibina, Olga, Foschi, Matteo, Grand’Maison, Francois, John, Nevin, Grammond, Pierre, Terzi, Murat, Prévost, Julie, Barnett, Michael, Laureys, Guy, Van Hijfte, Liesbeth, Luis Sanchez-Menoyo, Jose, Blanco, Yolanda, Oh, Jiwon, McCombe, Pamela, Ramo Tello, Cristina, Soysal, Aysun, Prat, Alexandre ... Kalincik, Tomas (2024). Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 30 (9), 1163-1175. doi: 10.1177/13524585241267211 |
|
2024 Conference Publication Utilisation of high efficacy therapy for managing multiple sclerosis in AustraliaMcCombe, Pamela, Butzkueven, Helmut, Samjoo, Imtiaz, Barnett, Michael, Broadley, Simon, Walt, Anneke Van der, Merschhemke, Martin, Adlard, Nicholas, Burke, Naomi, Riley, Nicholas and Walker, Rob (2024). Utilisation of high efficacy therapy for managing multiple sclerosis in Australia. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.23 |
|
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase registryMigocki, Margaret, Walt, Anneke Van der, Butzkueven, Helmut, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Kalincik, Tomas, Macdonell, Richard, Slee, Mark and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase registry. ANZAN Annual Scientific Meeting 2024, Adelaide, SA Australia, 21-24 May 2024. London, United Kingdom: BMJ Group. doi: 10.1136/bmjno-2024-anzan.127 |
|
2024 Journal Article Generation of human induced pluripotent stem cell lines from sporadic, sporadic frontotemporal dementia, familial SOD1, and familial C9orf72 amyotrophic lateral sclerosis (ALS) patientsJiang, Leanne, Tracey, Timothy J., Gill, Melinder K., Howe, Stephanie L., Power, Dominique T., Bharti, Vanda, McCombe, Pamela A., Henderson, Robert D., Steyn, Frederik J. and Ngo, Shyuan T. (2024). Generation of human induced pluripotent stem cell lines from sporadic, sporadic frontotemporal dementia, familial SOD1, and familial C9orf72 amyotrophic lateral sclerosis (ALS) patients. Stem Cell Research, 78 103447, 1-6. doi: 10.1016/j.scr.2024.103447 |
|
2024 Journal Article The clinical relevance of MOG antibody testing in cerebrospinal fluidReynolds, Molly, Tan, Irene, Nguyen, Kristy, Merheb, Vera, Lee, Fiona X. Z., Trewin, Benjamin P, Lerch, Magdalena, Shah, Snehal, Wolfe, Nigel, Buzzard, Katherine, Lechner-Scott, Jeannette, Fabis-Pedrini, Marzena, Fok, Anthony, John, Nevin, Kneebone, Chris, Yiannikas, Con, Brown, David A., Kermode, Allan G., Reddel, Stephen, Dale, Russell C., Brilot, Fabienne, Ramanathan, Sudarshini, Adam, Robert, Andersen, Jane, Andrews, Ian, Antony, Jayne, Aouad, Patrick, Badve, Monica, Barnett, Michael H. ... on behalf of the Australasian MOGAD Study Group (2024). The clinical relevance of MOG antibody testing in cerebrospinal fluid. Annals of Clinical and Translational Neurology, 11 (9), 1-6. doi: 10.1002/acn3.52163 |
|
2024 Journal Article General neurology: Current challenges and future implicationsBassetti, Claudio Lino Alberto, Accorroni, Alice, Arnesen, Astri, Basri, Hamidon Bin, Berger, Thomas, Berlit, Peter, Boon, Paul, Charway-Felli, Augustina, Kruja, Jera, Lewis, Steven, Markowski, Michael, Medina, Marco Tulio, McComb, Pamela, Moro, Elena, Ozturk, Serefnur, Smith, Paul and Vuletic, Vladimira (2024). General neurology: Current challenges and future implications. European Journal of Neurology, 31 (6) e16237, 1-11. doi: 10.1111/ene.16237 |
|
2024 Journal Article A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicLal, Anoushka P., Foong, Yi Chao, Sanfilippo, Paul G., Spelman, Tim, Rath, Louise, Levitz, David, Fabis-Pedrini, Marzena, Foschi, Matteo, Habek, Mario, Kalincik, Tomas, Roos, Izanne, Lechner-Scott, Jeannette, John, Nevin, Soysal, Aysun, D’Amico, Emanuele, Gouider, Riadh, Mrabet, Saloua, Gross-Paju, Katrin, Cárdenas-Robledo, Simón, Moghadasi, Abdorreza Naser, Sa, Maria Jose, Gray, Orla, Oh, Jiwon, Reddel, Stephen, Ramanathan, Sudarshini, Al-Harbi, Talal, Altintas, Ayse, Hardy, Todd A., Ozakbas, Serkan ... Van der Walt, Anneke (2024). A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology, 271 (9), 5813-5824. doi: 10.1007/s00415-024-12518-7 |
|
2024 Journal Article Verbal and nonverbal fluency in amyotrophic lateral sclerosisBarker, Megan S., Ceslis, Amelia, Argall, Rosemary, McCombe, Pamela, Henderson, Robert D. and Robinson, Gail A. (2024). Verbal and nonverbal fluency in amyotrophic lateral sclerosis. Journal of Neuropsychology, 18 (2), 265-285. doi: 10.1111/jnp.12354 |
|
2024 Journal Article Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosisNona, Robert J., Henderson, Robert D. and McCombe, Pamela A. (2024). Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 25 (5-6), 452-464. doi: 10.1080/21678421.2024.2351187 |
|
2024 Journal Article Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyDekeyser, Cathérine, Hautekeete, Matthias, Cambron, Melissa, Van Pesch, Vincent, Patti, Francesco, Kuhle, Jens, Khoury, Samia, Lechner Scott, Jeanette, Gerlach, Oliver, Lugaresi, Alessandra, Maimone, Davide, Surcinelli, Andrea, Grammond, Pierre, Kalincik, Tomas, Habek, Mario, Willekens, Barbara, Macdonell, Richard, Lalive, Patrice, Csepany, Tunde, Butzkueven, Helmut, Boz, Cavit, Tomassini, Valentina, Foschi, Matteo, Sánchez-Menoyo, José Luis, Altintas, Ayse, Mrabet, Saloua, Iuliano, Gerardo, Sa, Maria Jose, Alroughani, Raed ... Laureys, Guy (2024). Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 95 (11), 1021-1031. doi: 10.1136/jnnp-2023-333307 |
|
2024 Journal Article Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndromeButzkueven, Helmut, Ponsonby, Anne-Louise, Stein, Mark S., Lucas, Robyn M., Mason, Deborah, Broadley, Simon, Kilpatrick, Trevor, Lechner-Scott, Jeannette, Barnett, Michael, Carroll, William, Mitchell, Peter, Hardy, Todd A., Macdonell, Richard, Mccombe, Pamela, Lee, Andrew, Kalincik, Tomas, van der Walt, Anneke, Lynch, Chris, Abernethy, David, Willoughby, Ernest, Barkhof, Frederik, Macmanus, David, Clarke, Michael, Andrew, Julie, Morahan, Julia, Zhu, Chao, Dear, Keith and Taylor, Bruce (2024). Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain, 147 (4), 1206-1215. doi: 10.1093/brain/awad409 |
|
2024 Journal Article Long-term efficacy and safety of Rituximab in the treatment of neuromyelitis optica spectrum disorderHayes, Michael Thomas Gerard, Adam, Robert J., McCombe, Pamela Ann, Walsh, Michael and Blum, Stefan (2024). Long-term efficacy and safety of Rituximab in the treatment of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 10 (2) 20552173241257876, 20552173241257876. doi: 10.1177/20552173241257876 |
|
2024 Journal Article Transient binocular vision loss and pain insensitivity in Klippel–Feil syndrome: a case reportUllah, Zeeshan, Zafar, Ayesha, Ishaq, Hira, Umar, Zainab, Khan, Amir, Badar, Yaseen, Din, Nizamud, Khan, Muhammad Fawad, McCombe, Pamela and Khan, Nemat (2024). Transient binocular vision loss and pain insensitivity in Klippel–Feil syndrome: a case report. Journal of Medical Case Reports, 18 (1) 137, 1-6. doi: 10.1186/s13256-024-04374-w |
|
2024 Journal Article Variation in resting metabolic rate affects identification of metabolic change in geographically distinct cohorts of patients with ALSHoldom, Cory J., Janse van Mantgem, Mark R., He, Ji, Howe, Stephanie L., McCombe, Pamela A., Fan, Dongsheng, van den Berg, Leonard H., Henderson, Robert D., van Eijk, Ruben, Steyn, Frederik J. and Ngo, Shyuan T. (2024). Variation in resting metabolic rate affects identification of metabolic change in geographically distinct cohorts of patients with ALS. Neurology, 102 (5) e208117, 1-11. doi: 10.1212/wnl.0000000000208117 |
|
2024 Journal Article Gut symptoms, gut dysbiosis and gut-derived toxins in ALSLee, Aven, Henderson, Robert, Aylward, James and McCombe, Pamela (2024). Gut symptoms, gut dysbiosis and gut-derived toxins in ALS. International Journal of Molecular Sciences, 25 (3) 1871, 1-25. doi: 10.3390/ijms25031871 |
|
2024 Journal Article Associations of postprandial ghrelin, liver‐expressed antimicrobial peptide 2 and leptin levels with body composition, disease progression and survival in patients with amyotrophic lateral sclerosisHowe, Stephanie L., Holdom, Cory J., McCombe, Pamela A., Henderson, Robert D., Zigman, Jeffrey M., Ngo, Shyuan T. and Steyn, Frederik J. (2024). Associations of postprandial ghrelin, liver‐expressed antimicrobial peptide 2 and leptin levels with body composition, disease progression and survival in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 31 (1) e16052, e16052. doi: 10.1111/ene.16052 |
|
2024 Journal Article Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programmeHardy, TA, Aouad, P, Barnett, MH, Blum, S, Broadley, S, Carroll, WM, Crimmins, D, Griffiths, D, Hodgkinson, S, Lechner-Scott, J, Lee, A, Malhotra, R, McCombe, P, Parratt, J, Plummer, C, Van der Walt, A, Martel, K and Walker, RA (2024). Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 10 (1) 20552173231226106, 20552173231226106. doi: 10.1177/20552173231226106 |
